Skip to main content

Role of Nanocarriers in Management of Non-Hodgkin Lymphoma

  • 1st Edition - March 27, 2026
  • Latest edition
  • Editors: Bhupendra G. Prajapati, Devesh U. Kapoor
  • Language: English

Role of Nanocarriers in Management of Non-Hodgkin Lymphoma is a pivotal resource that explores the transformative impact of nanotechnology on the diagnosis, treatment, and manage… Read more

Data Mining & ML

Unlock the cutting edge

Up to 20% on trusted resources. Build expertise with data mining, ML methods.

Description

Role of Nanocarriers in Management of Non-Hodgkin Lymphoma is a pivotal resource that explores the transformative impact of nanotechnology on the diagnosis, treatment, and management of non-Hodgkin’s lymphoma (NHL). This comprehensive guide bridges the gap between innovative research and clinical application, focusing on advancements in polymeric nanoparticles, lipid carriers, carbon nanotubes, and immunotherapy approaches. The book provides an in-depth analysis of current technologies and future directions in integrating nanocarriers into NHL management. Each chapter offers evidence-based insights and mechanisms of action, emphasizing the synergy between immunotherapy, precision medicine, and nanotechnology. This resource benefits its academic audience by equipping healthcare professionals with innovative strategies to improve treatment outcomes and inspiring researchers to explore novel therapeutic pathways. By fostering interdisciplinary collaboration among oncologists, pharmaceutical developers, and nanotechnology experts, the book ultimately guides future research to enhance patient care in the rapidly evolving field of non-Hodgkin’s lymphoma management.

Key features

  • Offers in-depth analyses of various nanocarriers and therapeutic approaches, detailing their mechanisms of action and future potential in non-Hodgkin lymphoma management
  • Emphasizes cutting-edge, individualized therapeutic strategies, highlighting innovative treatments like CAR T-cell therapy and mRNA approaches that are crucial for personalized patient care
  • Includes practical chapters that address combination therapies and holistic patient care strategies, ensuring that healthcare professionals can effectively implement the latest advancements in their clinical practice

Readership

Researchers, academics and post-graduate students in oncology, hematology, pharmacology, and biomedical engineering

Table of contents

1. Introduction to Non-Hodgkin’s Disease and Conventional Therapies

2. Immune Checkpoint Inhibitors in Non-Hodgkin’s Lymphoma Management

3. Exploring Polymeric Nanoparticles in Non-Hodgkin’s Lymphoma Management

4. Magnetic Nanoparticles in Non-Hodgkin’s Lymphoma Therapy: Advancements and Future Directions

5. Leveraging Nanostructured Lipid Carrier (NLCs) in Non-Hodgkin’s Lymphoma Management

6. Breakthrough in Antibody-Drug Conjugates for Non-Hodgkin’s Lymphoma Management

7. Targeted Non-Hodgkin’s Lymphoma Management with Carbon Nanotubes: Potential and Progress

8. Advancement in Non-Hodgkin’s Lymphoma Management Using Exosomes

9. Biological and Immunological Aspects of Vaccines for Non-Hodgkin’s Lymphoma Management

10. Immunotherapy and Radioimmunotherapy Approaches for Non-Hodgkin’s Lymphoma Management

11. Innovative mRNA Approach for Non-Hodgkin’s Lymphoma Management

12. Monoclonal Antibody and CAR T-Cell Therapy: A Novel Avenue in Non-Hodgkin’s Lymphoma Management

13. Combination of Nanocarrier with Chemotherapy for Non-Hodgkin’s Lymphoma Management

14. Patient Care in Non-Hodgkin’s Lymphoma Management

15. Regulatory Challenges and Approvals for Nanocarrier-Based Therapies

Product details

  • Edition: 1
  • Latest edition
  • Published: March 27, 2026
  • Language: English

About the editors

BP

Bhupendra G. Prajapati

Dr. Bhupendra Gopalbhai Prajapati is Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India, and serves as Adjunct Professor in the Department of Industrial Pharmacy at Silpakorn University, Thailand. His academic, research, and industry expertise focuses on lipid‑based formulations, nano‑ and microparticulate drug delivery systems, and strategies to enhance drug bioavailability. Dr. Prajapati has received several academic and professional honors recognizing excellence in teaching and research. He has made substantial scholarly contributions through research and review publications, book chapters, and edited volumes in pharmaceutical sciences. Actively engaged in postgraduate and doctoral mentoring, he supports research training in advanced drug delivery and formulation science. Dr. Prajapati also serves in editorial and section‑editor roles for international scientific publications, contributing to the advancement and quality of pharmaceutical research dissemination.

Affiliations and expertise
Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Waghodia, Vadodara, Gujarat, India

DK

Devesh U. Kapoor

Dr. Devesh U. Kapoor is Professor of Pharmaceutics at Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, affiliated with Gujarat Technological University. His academic and research expertise centers on pharmaceutics, nanodrug delivery, and modified‑release drug delivery systems. Dr. Kapoor has made extensive scholarly contributions through research and review publications, book chapters, and edited volumes with international publishers. He is actively involved in postgraduate and doctoral research supervision in advanced drug delivery technologies. His editorial experience includes serving in senior editorial roles for international journals across pharmacology, pharmaceutics, and biomedical sciences, along with regular peer‑review activity for a wide range of scientific journals. Dr. Kapoor has also secured competitive research and academic development funding and is a frequent invited speaker at national scientific meetings, workshops, and academic programs.

Affiliations and expertise
Professor, Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, India

View book on ScienceDirect

Read Role of Nanocarriers in Management of Non-Hodgkin Lymphoma on ScienceDirect